| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V76337 | 2-Aminoethanethiosulfonic S-Acid | 2937-54-4 | Thiotaurine (2-Aminoethanethiosulfonic S-Acid), a metabolic product of cystine, contains a sulfane sulfur atom that can be released as H(2)S, a gaseous molecule with a regulatory activity on inflammatory responses. |
|
V3570 | TL13-12 | 2229037-04-9 | TL13-12 is novel, potent and selective PROTAC degrader of anaplastic lymphoma kinase (ALK) with potential anticancer activity. |
|
V2469 | Tripeptide-10 Citrulline | 960531-53-7 | Tripeptide-10 citrulline (T10-C) is a biologically active peptide with anti-aging activities and has been reported to be used as an ingredient of cosmetics. |
|
V3940 | Ulevostinag (MK-1454) | 2082743-96-0 | Ulevostinag (MK-1454; MK1454) is an investigational small molecule STING agonist with potential immunomodulatory and anticancer activities. |
|
V3307 | Ulodesine (BCX4208) | 548486-59-5 | Ulodesine (formerly also known as BCX4208) is a novel and potent inhibitor of purine nucleoside phosphorylase (PNP) with the potential to be used for the treatment of psoriasis and gout. |
|
V4235 | Vasotide | Vasotide, D(Cys-Leu-Pro-Arg-Cys) [abbreviated as D(CLPRC)], is a novel and potent peptidomimetic compound that targets two retinal VEGF receptors (VEGFR-1 and VEGFR-2) and reduces pathological angiogenesis in murine and nonhuman primate models of retinal disease. | |
|
V4392 | VATINOXAN HCL | 130466-38-5 | Vatinoxan HCl/hydrochloride (also known as MK-467 hydrochloride and L-659066 hydrochloride) is a novel and potent peripheralα2 adrenergic receptorantagonist. |
|
V2134 | YKL-05-099 | 1936529-65-5 | YKL-05-099 (YKL05099) is a novel, potent and selective inhibitor of salt-inducible kinase (SIK) with the potential to be used for treatment of inflammatory disorders. |
|
V3960 | DIETHYL PYIMDC | 1821370-64-2 | Diethyl pyimDC is a novel inhibitor of human CP4H1 (collagen prolyl 4-hydroxylase 1). |
|
V4366 | VANIPREVIR | 923590-37-8 | Vaniprevir (formerly known as MK-7009) is a non-covalent competitive inhibitor of the hepatitis C virus (HCV) NS3/4A protease. |
|
V3638 | Epetraborole R-Mandelate | 1234563-15-5 | Epetraborole R-Mandelate (also known as GSK2251052 and AN3365) is a novel, potent and selective leucyl-tRNA synthetase (LeuRS) inhibitor, which inhibits protein synthesis by binding to the terminal adenosine ribose (A76) of leucyl-tRNA synthetase. |
|
V3473 | Cariprazine sulfate | Cariprazine (formerly known as MP-214 and RGH-188) is a novel and potent antipsychotic drug candidate that is in late-stage clinical development for the treatment of schizophrenia, as well as for bipolar disorder (manic/mixed and depressive episodes), and as an adjunctive agent for the treatment of major depressive disorder. | |
|
V4397 | SERLOPITANT | 860642-69-9 | Serlopitant (also known as VPD-737 and MK-0594) is a novel, potent and selectiveantagonist of Neurokinin-1 (NK-1)receptor which is being evuluated in clinical trials for the treatment of urinary incontinence and overactive bladder, while it was superior to placebo it provided no advantage over existing drugs, and the further development was discontinued. |
|
V3519 | Peliglitazar | 331744-64-0 | Peliglitazar is a novel dual α/γ PPAR (peroxisome proliferator-activated receptor) activator. |
|
V3666 | Napsagatran | 159668-20-9 | Napsagatran hydrate is a novel and specificinhibitor of extrinsic and intrinsic thrombin generation which inhibits clot-bound and free (fluid-phase) thrombin. |
|
V3615 | Tofimilast | 185954-27-2 | Tofimilast (also known as CP-325366) is a novel and potent PDE4 (phosphodiesterase 4) inhibitor. |
|
V4074 | Unifiram (DM 232) | 272786-64-8 | Unifiram (also known as DM-232), a piperazine derived ampakine-like drug, has potent nootropic effects in animal studies with significantly higher potency than piracetam. |
|
V3888 | Plazomicin (ACHN490) | 1154757-24-0 | Plazomicin (ACHN490; ACHN-490;Trade name:Zemdri) is a next-generation aminoglycoside antibacterial derived from sisomicin by appending a hydroxy-aminobutyric acid (HABA) substituent at position 1 and a hydroxyethyl substituent at position 6'. |
|
V3655 | Tezosentan | 180384-57-0 | Tezosentan (RO610612; Veletr; RO-610612) is a novel, non-selective and dual antagonist/inhibitor ofendothelian (ETA/ETB) receptor (pA2sof 9.5, 7.7 for ETAand ETB) with the potential to be used for the treatment of congestive heart failure. |
|
V2468 | Palmitoyl Tripeptide-1 | 1628252-62-9 | Palmitoyl tripeptide-1 is a fatty acid-modified peptide. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
